Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded

Executive Summary

FDA and industry plan to create more staff to help deal with simple and clarifying questions from emerging and experienced sponsors during the application review process as part of PDUFA V.

You may also be interested in...



PDUFA V: Communications Liaisons Will Help Find Answers, Not Give Them

OND Director John Jenkins warns that new communications staff will not be equipped to deal with specific technical issues, but should be able to answer general questions.

TB Regimen Could Pave Way For More FDA Involvement In Neglected Tropical Diseases

TB Alliance plans to seek FDA approval for its treatment regimen, which is beginning a Phase IIb trial, as the agency looks to respond to calls for a clearer and quicker pathway for NTD drugs.

Tropical Disease Development Partnerships Want More Help From U.S. FDA

The agency’s infrastructure is not attracting many of the Product Development Partnership sponsors, Aeras official says, but new draft guidance could help.

Related Content

Topics

UsernamePublicRestriction

Register

PS053463

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel